home / stock / cdtx / cdtx articles
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading lower by 24.4% to $0.52 Monday afternoon. The company announced a 1-for-20 reverse stock s...
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonst...
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara's Cloudbreak platform for the devel...
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak...
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak&...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Wednesday. The Dow traded down 0.57% to 34,44...
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 114% to $1.47. Palisade Bio transformed GI-focused pipeline through exclusive worldwide l...
Cidara Therapeutics Inc (NASDAQ: CDTX) shares are trading higher after the company announced that Janssen Pharmaceuticals Inc, a unit of&...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...